For help on how to get the results you want, see our search tips.
8 results
Medicine
Orphan designations Remove Orphan designations filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Medicine type
Conditional approval Remove Conditional approval filter
Orphan medicine Remove Orphan medicine filter
Orphan designation status
Withdrawn Remove Withdrawn filter
-
List item
Orphan designation: Infigratinib for: Treatment of cholangiocarcinoma
Date of designation: 21/08/2020, Withdrawn, Last updated: 08/11/2022 -
List item
Orphan designation: Sirolimus for: Treatment of chronic non-infectious uveitis
Date of designation: 30/08/2011, Withdrawn, Last updated: 30/08/2022 -
List item
Orphan designation: Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment- for: Treatment in haematopoietic stem cell transplantation
Date of designation: 27/06/2016, Withdrawn, Last updated: 28/02/2022 -
List item
Orphan designation: Donor T lymphocytes depleted ex-vivo of host alloreactive T cells using photodynamic treatment for: Treatment of acute myeloid leukaemia
Date of designation: 19/11/2014, Withdrawn, Last updated: 28/02/2022 -
List item
Orphan designation: Donor lymphocyte preparation depleted of functional alloreactive T-cells for: Prevention of graft-versus-host disease
Date of designation: 05/09/2008, Withdrawn, Last updated: 28/02/2022 -
List item
Orphan designation: [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride for: Treatment of tenosynovial giant cell tumour, localised and diffuse type
Date of designation: 19/03/2015, Withdrawn, Last updated: 02/02/2022 -
List item
Orphan designation: N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine (etarfolatide) for: Diagnosis of positive folate-receptor status in ovarian cancer
Date of designation: 10/09/2012, Withdrawn, Last updated: 07/12/2021 -
List item
Orphan designation: Mepolizumab for: Treatment of hypereosinophilic syndrome
Date of designation: 29/07/2004, Withdrawn, Last updated: 23/10/2020